Telormedix and SUPSI Receive Funding from CTI

The SUPSI team will be directed by Professor Andrea Danani, Head of Research at the Laboratory of Applied Mathematics and Physics in the Department of Innovative Technologies, whereas Telormedix’s contribution will be coordinated by Alcide Barberis, Head of Research and Collaborations. The project will focus on the characterization and optimization of target-specific interactions of TLR7 modulators and their mode of action in immune system cells. Computational modeling performed at SUPSI will provide theoretical information about the structure of the TLR7 receptor and domain-specific interactions with Telormedix’s compounds. Telormedix will then be able to accurately predict the biochemical and biological properties of select drug candidates, which will be further tested and verified in molecular and cellular studies.

Johanna Holldack, CEO of Telormedix, commented: “We are delighted that CTI have recognized the potential of Telormedix’s TLR7-targeted molecules and look forward to working in collaboration with SUPSI. The knowledge acquired during this research collaboration will accelerate and focus the drug optimization process leading to GLP IND-enabling studies, which will allow us to bring our drug candidates through subsequent clinical phases.”

“We are truly excited to be working with Telormedix, studying target-specific interactions of TLR7 modulators and their mode of action in the immune system. We hope that a computational approach to this research will help Telormedix further develop their promising selection of drug candidates for the treatment of cancer and autoimmune diseases.” added Andrea Danani.